CDK10 and neoplasm: Although a recent study argued that CDK10 is a candidate therapeutic target for colorectal adenocarcinomas (Weiswald et al., 2017), a number of reports indicate that CDK10 acts as a tumor suppressor in various cancers of the digestive system, including biliary tract cancer (Yu et al., 2012), hepatocellular carcinomas (Zhong et al., 2012), gastric carcinomas (Zhao et al., 2017; You et al., 2018), and in nasopharyngeal carcinomas (You et al., 2013), gliomas (Li et al., 2018) and advanced breast cancers (You et al., 2015).